NSCLC Videos

Videos

Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC

05/27/2020

David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.

David Carbone, MD, PhD, comments...

05/27/2020

Oncology

Videos

Ongoing Trial Will Assess Trastuzumab Deruxtecan–Pembrolizumab Combo for Breast Cancer, NSCLC

05/27/2020

Hope Rugo, MD, looks forward to the safety and efficacy findings of an ongoing study examining trastuzumab deruxtecan plus pembrolizumab for breast cancer and NSCLC.

Hope Rugo, MD, looks forward to...

05/27/2020

Oncology

Videos

Pembrolizumab Added to Chemo Maintains OS, PFS Benefits in Metastatic NSCLC

05/27/2020

Yasir Elamin, MD, discusses the clinical significance of the KEYNOTE-189 clinical trial evaluating the use of chemo plus pembrolizumab for metastatic, nonsquamous NSCLC.

Yasir Elamin, MD, discusses the...

05/27/2020

Oncology

Videos

The Role of Antiangiogenics in NSCLC

05/14/2020

Helen Ross, MD, discusses the role of antiangiogenics over time in treating NSCLC.

Helen Ross, MD, discusses the...

05/14/2020

Oncology

Videos

Treatment of ALK-Positive and ROS1 Rearrangements in NSCLC

05/07/2020

Helen Ross, MD, Director of Thoracic Malignancies Program, Mayo Clinic, Scottsdale, Arizona, discusses the role of ALK-Positive and ROS1 rearrangements in patients with NSCLC and treatment options.

Helen Ross, MD, Director of...

05/07/2020

Oncology

Videos

Managing Oncogenic Driver Mutations in NSCLC

04/16/2020

Helen Ross, MD, discusses the need to screen patients with NSCLC for driver mutations via NGS at diagnosis and after progression to help select first-, second-, and third-line targeted therapies.

Helen Ross, MD, discusses the...

04/16/2020

Oncology

Videos

Lyudmila Bazhenova, MD, Talks About Immune-Related AEs in Lung Cancer

03/25/2020

Dr Bazhenova talks about the management of immune-related adverse events in patients with lung cancer.

Dr Bazhenova talks about the...

03/25/2020

Oncology

Videos

Remarkable Breakthroughs in the Treatment of Advanced NSCLC

03/22/2020

Martin J. Edelman, MD, discusses how the treatment landscape for advanced NSCLC has evolved in recent years.

Martin J. Edelman, MD, discusses...

03/22/2020

Oncology

Videos

The Future of Lung Cancer Screening

03/03/2020

James L. Mulshine, MD, talks about what the future holds vis-a-vis advancements in lung cancer screening.

James L. Mulshine, MD, talks...

03/03/2020

Oncology

Videos

Fadi Braiteh, MD, Discusses the Ins and Outs of Entrectinib Therapy for NSCLC

12/03/2019

Dr Braiteh spoke in detail about the use of entrectinib therapy in patients with NSCLC at the 2019 Perspectives in Thoracic Oncology meeting.

Dr Braiteh spoke in detail about...

12/03/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology